home / stock / fblg / fblg news

FBLG News and Press, FibroBiologics Inc. From 11/19/25

Stock Information
Company Name: FibroBiologics Inc.
Stock Symbol: FBLG
Market: NASDAQ
Website: fibrobiologics.com
Menu
FBLG FBLG Quote FBLG Short FBLG News FBLG Articles FBLG Message Board
Get FBLG Alerts

News, Short Squeeze, Breakout and More Instantly...
FBLG - FibroBiologics raises $4M in gold-funded registered direct offering

2025-11-19 08:42:11 ET More on FibroBiologics Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBiologics Financial information for FibroBiologics Read the full article on Seeking Alpha For further details see: ...
FBLG - FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chron...

FBLG - FibroBiologics GAAP EPS of -$0.13

2025-11-03 13:51:29 ET More on FibroBiologics Seeking Alpha’s Quant Rating on FibroBiologics Historical earnings data for FibroBiologics Financial information for FibroBiologics Read the full article on Seeking Alpha For further details see: ...

FBLG - FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients Preparing to submit Investigational New Drug applications for the treatment of psoriasis with ...
FBLG - FibroBiologics to Present at Bio-Europe 2025

HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics to Present at the 2025 ThinkEquity Conference

HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts a...

FBLG - FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...
FBLG - FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...

FBLG - FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...

FBLG - FibroBiologics Advances Bone Marrow Organoid Platform with Potential in Cancer and Immune Therapies

2025-09-10 12:31:23 ET FibroBiologics (NASDAQ: FBLG ), a biotech company developing fibroblast -based cell therapies, announced new progress with its bone marrow organoid platform, underscoring its potential in cancer research and immune-related disease treatment. The techno...
Previous 10 Next 10